News | SCAI | February 18, 2025

Study: Lower Cardiovascular Risk in Type 1 Diabetes vs. Type 2 Diabetes

New research highlights the differences between the two types of diabetes and provides new insights that could influence future treatment approaches.

Getty Images


Feb. 12, 2025 — A new study published in JSCAI has revealed a lower risk of cardiovascular events for patients with Type 1 diabetes (often called juvenile diabetes) compared to those with Type 2 diabetes. The research highlights the differences between the two types of diabetes and provides new insights that could influence future treatment approaches. 

“The study's findings suggest that the cardiovascular risk associated with Type 1 diabetes is lower than previously thought, which has important implications for managing these patients. Our findings indicate that Type 1 diabetes is associated with a significantly lower risk of cardiovascular events compared to Type 2 diabetes, even after adjusting for various confounders such as age, diabetes control, and kidney function,” said Andrew M. Goldsweig, MD, MSc, FSCAI, director of cardiovascular clinical research at Baystate Medical Center in Springfield, MA. “The power of big data amplifies the results: With the enormous population included in this analysis, we were able to identify a large number of people with Type 1 diabetes and compare them to those with Type 2 diabetes, providing a comprehensive understanding of the differences in cardiovascular risk." 

For the study, Goldsweig collaborated with Baystate pediatric endocrinologist Bracha Goldsweig, MD, to examine the Veradigm Metabolic Registry, operated in collaboration with the American College of Cardiology, which includes longitudinal records of 1.5 million individuals from over 700 facilities. The analysis identified nearly 6,000 people with Type 1 diabetes and compared their cardiovascular event rates to those of people with Type 2 diabetes. When controlling for confounders, the results showed that people with Type 1 diabetes had lower rates of myocardial infarction (MI), percutaneous coronary intervention (PCI), stroke, and limb ischemia compared to people with Type 2 diabetes. There was no significant difference in the rates of bypass surgery between the two groups.  

Dr. Bracha Goldsweig emphasized the importance of distinguishing between patients with each type of diabetes to develop targeted treatment strategies: 

"Type 1 and Type 2 diabetes are fundamentally different diseases. People with Type 1 diabetes do not produce insulin, while people with Type 2 diabetes have insulin insensitivity. Our study shows that it is not appropriate to manage all people with diabetes identically, and dedicated studies for Type 1 diabetes are necessary to understand the best treatment approaches,” Dr. Bracha Goldsweig said. “People with Type 1 diabetes now live normal lifespans, and it is crucial to study this population to ensure they receive the best possible care.” 

This research marks the first time the Doctors Goldsweig, who are spouses, have published together, highlighting the importance of multidisciplinary collaboration. An Early Career Research Grant (ECRG) from the Society for Cardiovascular Angiography and Interventions (SCAI) supported the project. 

"We were excited to work together in this area where our fields overlap," Dr. Andrew Goldsweig said. "The support from SCAI’s ECRG grant was crucial in making this research possible." 

Click here to learn more.


Related Content

News | SCAI

May 7, 2024 — Medtronic announced the release of important clinical outcomes in two leading transcatheter valve ...

Home May 07, 2024
Home
News | SCAI

May 7, 2024 — Women and black patients were less frequently treated with minimally invasive therapy compared to men or ...

Home May 07, 2024
Home
News | SCAI

May 1, 2024 — The annual Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific ...

Home May 01, 2024
Home
News | SCAI

June 1, 2023 — New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor ...

Home June 01, 2023
Home
News | SCAI

May 24, 2023 — The largest interventional study focused on pulmonary embolisms highlighted importance of rapid removal ...

Home May 24, 2023
Home
Feature | SCAI | Christine Book

May 23, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) welcomed its 46th President and 2023 ...

Home May 23, 2023
Home
News | SCAI

May 19, 2023 — Findings from a study examining the relationship between marijuana use and peripheral artery disease (PAD ...

Home May 19, 2023
Home
News | SCAI

February 7, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) announced the second application ...

Home February 07, 2023
Home
News | SCAI

January 18, 2023 — the Society for Cardiovascular Angiography & Interventions (SCAI) announced four recipients of their ...

Home January 18, 2023
Home
News | SCAI

December 8, 2022 — The Society for Cardiovascular Angiography & Interventions (SCAI), a leading nonprofit medical ...

Home December 08, 2022
Home
Subscribe Now